Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

Active:	Yes
Cancer Type:	Solid Tumor Unknown Primary	NCT ID:	NCT03785249
Trial Phases:	Phase I Phase II	Protocol IDs:	849-001 (primary) NCI-2019-01032
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Mirati Therapeutics
NCI Full Details:	http://clinicaltrials.gov/show/NCT03785249

Summary

This study will evaluate the safety, tolerability, drug levels, molecular effects, and
clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have
a KRAS G12C mutation.

Objectives

This study will evaluate the safety, tolerability, pharmacokinetics, metabolites,
pharmacodynamics, and clinical activity of MRTX849 (adagrasib) in patients with advanced
solid tumors with a KRAS G12C mutation. MRTX849 (adagrasib) is an orally-available small
molecule inhibitor of KRAS G12C.

Treatment Sites in Georgia

Northside Hospital Cancer Institute
1000 Johnson Ferry Road NE
Atlanta, GA 30342
404-303-3355
www.northside.com

University Cancer and Blood Center, LLC - Athens Medical Oncology
3320 Old Jefferson Road
Building 800
Athens, GA 30607
www.universitycancer.com

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.